Scholarlink

Objective <p>To evaluate the utility of N-terminal pro-brain natriuretic peptide (NT pro-BNP) for screening and diagnosis of chronic pulmonary hypertension (cPH) in extremely low gestational age neonates (ELGANs &lt; 28 weeks gestational age [GA]).</p> Methods <p>We conducted a retrospective cohort study analyzing paired echocardiogram results and serum NT pro-BNP concentrations (ng/L) in ELGANs. The accuracy of NT pro-BNP for diagnosing cPH and determining the optimal cut-off for cPH screening and diagnosis was evaluated using receiver operating characteristics (ROC) curves and Youden’s index, respectively.</p> Results <p>Among the 35 included ELGANs, the area under the ROC curve for diagnosing cPH using NT pro-BNP levels combined with GA &lt; 25 weeks and BPD was 0.70 (95% CI: 0.51-0.89). An NT pro-BNP value of 1129 showed a sensitivity of 85%, while a value of 2674 demonstrated a specificity of 95%, indicating its potential role in screening and diagnosing cPH.</p> Conclusions <p>NT pro-BNP is a promising biomarker for screening and diagnosing cPH in ELGANs.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Can N-terminal pro-brain natriuretic peptide accurately diagnose chronic pulmonary hypertension among extremely low gestational age neonates: A Retrospective Cohort Study

  • 期刊论文

  • 发表日期：

    2025年11月13日

查看全文
  • Macarena Garcia-Gozalo,
  • Amish Jain,
  • Dany E. Weisz,
  • Bonny Jasani

摘要

Objective

To evaluate the utility of N-terminal pro-brain natriuretic peptide (NT pro-BNP) for screening and diagnosis of chronic pulmonary hypertension (cPH) in extremely low gestational age neonates (ELGANs < 28 weeks gestational age [GA]).

Methods

We conducted a retrospective cohort study analyzing paired echocardiogram results and serum NT pro-BNP concentrations (ng/L) in ELGANs. The accuracy of NT pro-BNP for diagnosing cPH and determining the optimal cut-off for cPH screening and diagnosis was evaluated using receiver operating characteristics (ROC) curves and Youden’s index, respectively.

Results

Among the 35 included ELGANs, the area under the ROC curve for diagnosing cPH using NT pro-BNP levels combined with GA < 25 weeks and BPD was 0.70 (95% CI: 0.51-0.89). An NT pro-BNP value of 1129 showed a sensitivity of 85%, while a value of 2674 demonstrated a specificity of 95%, indicating its potential role in screening and diagnosing cPH.

Conclusions

NT pro-BNP is a promising biomarker for screening and diagnosing cPH in ELGANs.